Evidence map›Paper›PMID 40998804›Full record

ArticleNature communications2025

Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer.

Saskia Hartner, Hanie Abolfathi, Morteza Rezanejad, Bridget Liu, Elham Karimi, Dakota Rogers, Mark Sorin, Samuel Doré, Lysanne Desharnais, Michèle Orain and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Saskia Hartner *Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0009-0006-1030-1191
Hanie Abolfathi *Department of Molecular Medicine, Université Laval, Quebec, QC, Canada.ORCID http://orcid.org/0009-0008-3633-3452
Morteza RezanejadRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Bridget LiuRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Elham KarimiRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Dakota RogersRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Mark SorinRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Samuel DoréRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Lysanne DesharnaisRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Michèle OrainInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, QC, Canada.
William EnlowInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, QC, Canada.
Andréanne GagnéInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0000-0002-3833-4159
Yuhong WeiRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Yohan BosséInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0000-0002-3067-3711
Daniela F QuailRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-6969-3250
Philippe JoubertInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, QC, Canada. philippe.joubert@criucpq.ulaval.ca.
Logan A WalshRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada. logan.walsh@mcgill.ca.ORCID http://orcid.org/0000-0001-8771-2577

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is a molecularly diverse form of lung cancer characterized by distinct oncogenic driver mutations that influence both tumour biology and clinical outcomes. Understanding the interplay between these oncogenic drivers and the tumour microenvironment (TME) is crucial for improving therapeutic strategies and patient management. Here, we investigate the impact of driver mutations on the composition and spatial architecture of the TME in LUAD. Using imaging mass cytometry (IMC), we analyse tumour samples from 157 LUAD patients, integrating genomic and clinical data to link specific mutations with tumour characteristics. Unique patterns are associated with mutated KRAS and EGFR tumours with TP53 co-mutations, suggesting these co-mutations reshape the TME and promote resistance to tyrosine kinase inhibitors (TKIs). Overall, our findings highlight the complex interplay between oncogenic driver mutations and the TME in LUAD, underscoring the importance of integrating genomic and cellular data to understand the underlying tumour behaviour and prognosis.

Indexed as

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationTumor MicroenvironmentAgedDrug Resistance, NeoplasmErbB ReceptorsFemaleHumansMaleMiddle AgedOncogenesPrognosisProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)EGFR protein, humanErbB ReceptorsKRAS protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID40998804
PMCPMC12462439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.